Therefore, our results highlighted a key role for Treg cells in DLBCL progression and suggested that targeting ICOS/ICOSL pathway may be an alternative immunotherapy for DLBCL treatment. The gene discussed is ICOS; the disease is diffuse large B-cell lymphoma.